Effect of Glucosamine Sulfate on Hip Osteoarthritis: A Randomized Trial
Effect of Glucosamine Sulfate on Hip Osteoarthritis: A Randomized Trial
April 8, 2008
THE WEEK IN CHIROPRACTIC

Effect of Glucosamine Sulfate on Hip Osteoarthritis: A Randomized Trial

Background: The effectiveness of glucosamine sulfate as a symptom and disease modifier for osteoarthritis is still under debate.

Objective: To assess whether glucosamine sulfate has an effect on the symptoms and structural progression of hip osteoarthritis during 2 years of treatment.
Design: Randomized, controlled trial.

Setting: Primary care in the Netherlands.

Patients: 222 patients with hip osteoarthritis who were recruited by their general practitioner. Patients were eligible if they met the American College of Rheumatology clinical criteria for hip osteoarthritis.

Intervention: 2 years of treatment with 1500 mg of oral glucosamine sulfate or placebo once daily.

Measurements: Primary outcome measures were Western Ontario and McMaster Universities (WOMAC) pain and function subscales over 24 months and joint space narrowing after 24 months. The main secondary outcome measures were WOMAC pain, function, and stiffness after 3, 12, and 24 months.

Results: At baseline, both groups were similar in demographic and clinical variables. Overall, WOMAC pain did not differ (mean difference [glucosamine sulfate minus placebo], -1.54 [95% CI, -5.43 to 2.36]), nor did WOMAC function (mean difference, -2.01 [CI, -5.38 to 1.36]). Joint space narrowing also did not differ after 24 months (mean difference, -0.029 [CI, -0.122 to 0.064]). Only 1 of the sensitivity analyses, based on extreme assumptions regarding missing assessments due to total hip replacement, provided results consistent with a glucosamine effect.
Limitations: Twenty patients had total hip replacement during the trial. Half of the patients had a Kellgren and Lawrence score of 1.

Conclusion: Glucosamine sulfate was no better than placebo in reducing symptoms and progression of hip osteoarthritis.

Rozendaal RM, et al. Annals of Internal Medicine. February 2008; Vol. 148, Iss. 4, pp. 268-277.
----------------------------------------------------------------------
Inclusion of information in The Week in Chiropractic does not imply endorsement from FCER nor does inclusion imply agreement with FCERÌs views.
For a complete copy of an article abstracted in "Research Review," please check your local medical or chiropractic college library.

© 2008 Foundation for Chiropractic Education and Research
You can reprint any part of this newsletter with the following attribution: ÏReprinted with permission of the Foundation for Chiropractic Education and Research, The Week in Chiropractic. Subscribe for free at www.fcer.org.
FCER Members can now access the Manual and Alternative Natural Therapy Index System (MANTIS) database for FREE. For more informationÛincluding Account number and Password (required for access to MANTIS)Ûplease call FCER at 800-637-6244, or send a request for information to FCER@fcer.org. Not a member? Find out how at www.FCER.org. ----------------------------------------------------------------------
The Week in Chiropractic is a weekly e-mail newsletter published by the Foundation for Chiropractic Education and Research, PO Box 400, 380 Wright Rd, Norwalk, IA 50211, Tele: 800-622-6309, Fax: 515-981-9427, E-mail FCER@fcer.org. Send editorial correspondence to Robin R. Merrifield, Editor, 1304 Perry Ave, Bremerton, WA 98310. E-mail: FCERedit@aol.com.
----------------------------------------------------------
Comments: 0
Votes:20